MyProstateScore 2.0 expert shares the next generation of prostate cancer screening
Jeffrey Tosoian, M.D., MPH, an assistant professor in the Division of Urologic Oncology at Vanderbilt University Medical Center, was interviewed by Vanderbilt Health to explain how he and his University of Michigan research team set out to find markers in blood or urine that are specific for higher-grade, clinically significant cancers.
The team successfully identified 56 markers that met their criteria, all detectable in urine. Further bioinformatic and biostatistical analyses and various modeling approaches yielded a panel of 18 markers predictive of higher-grade, clinically significant cancers.
“It’s a third generation of prostate cancer biomarkers,” Tosoian said. “The first generation was prostate-specific antigen [PSA], the second was MyProstateScore and other cancer-specific tests. The new model is focused on the high-grade cancers we really need to diagnose and treat. This has potential to substantially improve clinical practice, as well as patients’ experience of the screening process.”
Click here to read the full article from Vanderbilt Health.